Loading...

APUS APIMEDS PHARMACEUTICALS US INC Delisting Actions 8-K Filing

PMDS

PS

APIMEDS PHARMACEUTICALS US INC

(APUS)

2026 8-K

New CEO Appointment

Settlement Agreement

Delisting Notice

Filings Delay Notification

Stockholder Consent Nullified

Board Changes Invalidated

Board Restructuring

Stock Split Announcement

Director Resignations

Merger Amendment Notice

Merger Agreement

CEO Salary Increase

Bylaw Amendment

Investor Meetings

Debt Restructuring

External Links:

On April 17, 2026, Apimeds Pharmaceuticals US, Inc. received a notice from the NYSE for not meeting listing requirements due to a late Form 10-K filing for 2025. The company has six months to comply, or else further actions may be taken.

AI Assistant

APIMEDS PHARMACEUTICALS US INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.